Objective: To study the value of two outpatient urine tests with regard to the diagnosis and recurrence of bladder tumors. Methods: Fifty patients with a history of superficial bladder cancer were evaluated with urinary NMP22TM levels (cutoff level 10 U/ml), bladder wash karyometry (low versus intermediate and high risk) and cystoscopy. All patients were followed for 1 year. Results: Diagnostic negative and positive predictive values (NPV and PPV) of the tests were, respectively: NMP22 91.2 and 56.3%, and karyometry 80 and 33.3%. Prognostic NPV and PPV with regard to a subsequent recurrence were, respectively: NMP22 77.8 and 27.3%, and karyometry 82.6 and 50%. Conclusion: The diagnostic value of NMP22 is good. Since the 3 false-negative results were in low-stage and low-grade lesions, this test could be used as a prescreening for cystoscopy. The NPV of these tests with regard to tumor recurrence is around 80%, but only karyometry has a significant PPV. Change in the follow-up policy on the basis of these tests remains difficult. In patients with neobladders NMP22 appears to be of little use, because of the high urinary NMP22 levels in the absence of malignancy.

Badalament RA, Hermansen DK, Kimmel M, Gay H, Herr HW, Fair W, Whitmore WF Jr, Melamed MR: The sensitivity of bladder wash flow cytometry, bladder wash cytology and voided cytology in the detection of bladder carcinoma. Cancer 1987;60:1423–1427.
Berezney R, Coffey DS: Identification of a nuclear protein matrix. Biochem Biophys Res Commun 1974;60:1410–1417.
Berezney R, Coffey DS: Nuclear protein matrix: Association with newly synthesized DNA. Science 1975;189:291–293.
Fey EG, Bangs P, Sparks C, Odgren P: The nuclear matrix: Defining structural and functional roles. Crit Rev Eukaryotic Gene Expr 1991;1:127–144.
Getzenberg RH: The nuclear matrix and the regulation of gene expression: Tissue specificity. J Cell Biochem 1984;55:22–31.
Fey EG, Penman S: Nuclear matrix proteins reflect cell type and origin in cultured human cells. Proc Natl Acad Sci USA 1988;85:121–125.
Partin AW, Getzenberg RH, CarMichael JM, Vindivich D, Yoo J, Epstein JI, Coffey DS: Nuclear matrix protein patterns in human benign prostatic hyperplasia and prostate cancer. Cancer Res 1993;53:744–746.
Khanuja PS, Lehr JE, Soule HD, Gehani SK, Noto AC, Choudhury S, Chen R, Pienta KJ: Nuclear matrix proteins in normal and breast cancer cells. Cancer Res 1993;53:3394–3398.
Wisecarver JL, Synovec MS, Pirrucello S, Linder J: Marking characteristics of anti-nuclear matrix protein NM200.4 in human breast carcinomas and normal human tissues. J Clin Lab Anal 1993;7:134–138.
Keesee SK, Meneghini MD, Szaro RP, Wu YJ: Nuclear matrix proteins in human colon cancer. Proc Natl Acad Sci USA 1994;91:1913–1916.
Bidwell JP, Fey EG, van Wijnen AJ, Penman S, Stein JL, Lian JB, Stein GS: Nuclear matrix proteins distinguish normal diploid osteoblasts from osteosarcoma cells. Cancer Res 1994;54:28–32.
Getzenberg RH, Konety BR, Oeler TA, Quigley MM, Hakam A, Becich MJ, Bahnson RR: Bladder cancer-associated nuclear matrix proteins. Cancer Res 1996;56:1690–1694.
Donat TL, Sakr W, Lehr JE, Pienta KJ: Unique nuclear matrix protein alterations in head and neck squamous cell carcinomas: Intermediate biomarker candidates. Otolaryngol Head Neck Surg 1996;114:387–393.
Miller TE, Beausang LA, Winchell LF, Lidgard GP: Detection of nuclear matrix proteins in serum from cancer patients. Cancer Res 1992;52:422–427.
Soloway MS, Briggman V, Carpinito GA, Chodak GW, Church PA, Lamm KL, Lange P, Messing E, Pasciak RM, Reservitz GB, Rukstalis DB, Sarosdy MF, Stadler WM, Thiel RP, Hayden CL: Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol 1996;156:363–367.
van der Poel HG, Witjes JA, van Stratum P, Boon ME, Debruyne FMJ, Schalken JA: Quanticyt: Karyometric analysis of bladder washing for patients with superficial bladder cancer. Urology 1996;48:357–364.
van der Poel HG, Boon ME, van Stratum P, Ooms EC, Wiener H, Debruyne FM, Witjes JA, Schalken JA, Murphy WM: Conventional bladder wash cytology performed by 4 experts versus quantitative image analysis. Mod Pathol 1997;10:976–982.
NMP22TM Principal Investigators Symposium: Trial of NMP22TM as an indicator of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. Proceedings of the meeting, 10 Feb 1995.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.